TORII PHARMA, 35% Decrease in Ordinary Profit for The Current Fiscal Year

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Feb 7, 2025 3:30 pm JST Earnings

4551 TORII PHARMACEUTICAL CO., LTD. 【J-GAAP】

Earnings Report

TORII PHARMACEUTICAL CO., LTD. <4551> [TSE Prime] announced its financial results after the market closed on February 7th (15:30). The ordinary profit (non-consolidated) for the fiscal year ending December 2024 expanded 30.5% from the previous period to 6.92 billion yen. However, for the fiscal year ending December 2025, the profit is expected to drop by 35.0% from the previous period to 4.5 billion yen.

In the most recent three-month period, from October to December (4Q), the ordinary profit grew 12.4% from the same period last year, reaching 2.24 billion yen. The operating profit margin rose from 11.8% in the same period last year to 12.5%.

Kabutan News

Actual Results

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	48,896	5,540	5,537	3,944	140.4	100	Feb 10, 2023	J-GAAP
Dec, 2023	54,638	5,035	5,307	4,119	146.6	120	Feb 9, 2024	J-GAAP
Dec, 2024	60,426	6,798	6,926	5,042	179.4	120	Feb 7, 2025	J-GAAP
YoY	+10.6%	+35.0%	+30.5%	+22.4%	+22.4%

Full Year Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2024 Guidance	61,200	6,700	6,800	5,100	181.4	120	Oct 31, 2024	J-GAAP
Dec, 2024 Results	60,426	6,798	6,926	5,042	179.4	120	Feb 7, 2025	J-GAAP
Revision Rate	-1.3%	+1.5%	+1.9%	-1.1%	-1.1%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	28,309	3,141	2,985	2,221	79.0	60	Jul 31, 2024	J-GAAP
Jan - Jun, 2025 Guidance	ー	ー	ー	ー	－	60	Feb 7, 2025	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	54,638	5,035	5,307	4,119	146.6	120	Feb 9, 2024	J-GAAP
Dec, 2024	60,426	6,798	6,926	5,042	179.4	120	Feb 7, 2025	J-GAAP
Dec, 2025 Guidance	64,700	4,100	4,500	3,400	120.9	120	Feb 7, 2025	J-GAAP
YoY	+7.1%	-39.7%	-35.0%	-32.6%	-32.6%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	15,506	1,824	1,992	1,751	62.3	11.8	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	13,451	1,383	1,166	878	31.3	10.3	Apr 26, 2024	J-GAAP
Apr - Jun, 2024	14,858	1,758	1,819	1,343	47.8	11.8	Jul 31, 2024	J-GAAP
Jul - Sep, 2024	15,024	1,520	1,701	1,304	46.4	10.1	Oct 31, 2024	J-GAAP
Oct - Dec, 2024	17,093	2,137	2,240	1,517	54.0	12.5	Feb 7, 2025	J-GAAP
YoY	+10.2%	+17.2%	+12.4%	-13.4%	-13.4%